Why enGene Therapeutics Inc.’s (ENGN) Stock Is Up 6.69%
As of Wednesday, November 18, enGene Therapeutics Inc.’s ENGN share price has surged by 6.69%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
| Share Statistics | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $114.9 | $208.2 | 24% |
|
| Shares Out (Mil) | 69.7 | 55.4 | 54% |
|
| Institutional Ownership | 99.3% | 92.9% | 86% |
|
| Float (Mil) | 32.3 | 40.7 | 37% |
|
| Beta | -0.27 | 1.00 | 2% |
|
| Avg Daily Volume (000s) | 2,712 | 570 | 84% |
|
| Price Change (52-week) |
(79.9%) | 40.7% | 9% |
|
| Growth | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (50.7%) | (10.3%) | 7% |
|
| EPS (5yr) | 17.6% | 15.5% | 64 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (69.8%) | (15.7%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($0.468) | ($1.820) | ($1.595) | |
| Month Ago EPS | ($0.458) | ($1.809) | ($1.454) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.410) | ($1.727) | ($1.405) | |
| Year/Year Chg | 0.4% | (20.7%) | (56.1%) | |
| Financials | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($130) | ($44) | 9% |
|
| EPS (TTM) | ($2.020) | ($1.400) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($103) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $-0 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $31 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | ($105) | $138 | 0% |
|
| Valuation | ENGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.50 | 1.96 | 12% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (48.8%) | (47.4%) | 11% |
|
| ROE | (60.5%) | (51.6%) | 13% |
|
| Liabilities to Assets | 20.1% | 29.7% | 13% |
|
| F-Score | 1 | 3 | 1% |
|
enGene Therapeutics Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors